Correction to: Acta Pharmacologica Sinica https://doi.org/10.1038/s41401-021-00613-8, published online 24Â Feb 2021
The author order and affiliation should be corrected to
Ya-jin Liao1,2,3,4#*, Rui-yuan Pan2#, Xiang-xi Kong2#, Yong Cheng1, Lu Du2, Zhen-chao Wang3, Chao Yuan2, Jin-bo Cheng1, Zeng-qiang Yuan2, Hai-yan Zhang3*
1. Center on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing 100081, China.
2. Brain Science Center, Beijing Institute of Basic Medical Sciences, Beijing 100850, China.
3. Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China.
4. NHC Key Laboratory of Birth Defects Research, Prevention and Treatment, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410005, China.
#These authors contributed equally to this work.
* Corresponding author:
Ya-jin Liao Email: lyajin@muc.edu.cn
Hai-yang Zhang Email: haiyansl@163.com
The authors apologize that the lane 1 of the pro-Casp-1 band in Figure 1b was missed due to our neglect when preparation of the manuscript, in the initially published version of this article.
The Figure 1b is revised as below.
Below is the original picture of the pro-Casp-1 band of Figure 1b
The authors apologize for any inconvenience caused to the journal and readers
Author information
Authors and Affiliations
Corresponding authors
Additional information
The original article can be found online at https://doi.org/10.1038/s41401-021-00613-8.
Rights and permissions
About this article
Cite this article
Liao, Yj., Pan, Ry., Kong, Xx. et al. Correction: 1,2,4-Trimethoxybenzene selectively inhibits NLRP3 inflammasome activation and attenuates experimental autoimmune encephalomyelitis. Acta Pharmacol Sin 43, 504 (2022). https://doi.org/10.1038/s41401-021-00670-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41401-021-00670-z
This article is cited by
-
The role of inflammasomes in human diseases and their potential as therapeutic targets
Signal Transduction and Targeted Therapy (2024)